Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.

Belite Bio completes enrollment in the pivotal PHOENIX trial, advancing Tinlarebant's potential to treat geographic atrophy.

Talcott’s presentation focused on phase 2 clinical trial results of a therapeutic in development: EYP-1901, which aims to reduce treatment burden for wet AMD. This candidate is a bioerodible, ...

At the 2025 Annual Meeting, I had the privilege of 1 I have been working on over the past year—exploring how retinal imaging might help detect early signs of Alzheimer disease (AD), especially in ...